HLB bioStep (278650) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, HLB bioStep (278650) reported revenue of 74.1 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202574.1 billion KRW-8.6 billion KRW-20.3 billion KRW[source]
202458.2 billion KRW-13.0 billion KRW-9.7 billion KRW[source]
202352.8 billion KRW-1.3 billion KRW-54 million KRW[source]
202286.3 billion KRW6.4 billion KRW-2.9 billion KRW[source]
202164.4 billion KRW9.8 billion KRW11.5 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025135.9 billion KRW38.2 billion KRW97.7 billion KRW[source]
2024148.7 billion KRW36.0 billion KRW112.7 billion KRW[source]
2023162.9 billion KRW63.9 billion KRW98.9 billion KRW[source]
2022161.3 billion KRW95.6 billion KRW65.7 billion KRW[source]
202188.6 billion KRW26.2 billion KRW62.4 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
20253.1 billion KRW-5.5 billion KRW-2.6 billion KRW[source]
2024-11.7 billion KRW1.5 billion KRW-12.4 billion KRW[source]
20235.2 billion KRW55.7 billion KRW-7.0 billion KRW[source]
20226.5 billion KRW-80.8 billion KRW83.1 billion KRW[source]
20218.5 billion KRW-19.6 billion KRW9.2 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice